The authors reply

Affiliations

¹ Infectious Disease Division, The Alpert Medical School of Brown University, Providence, RI; Cooper Medical School of Rowan University, Camden, NJ; Department of Intensive Care, Erasme University Hospital, Brussels, Belgium; National Institutes of Health, Bethesda, MD; University of Pittsburgh School of Medicine, Pittsburgh, PA.

Comment

Steven M Opal et al. Crit Care Med. 2014 Dec.

. 2014 Dec;42(12):e798-9.

doi: 10.1097/CCM.0000000000000681.

¹ Infectious Disease Division, The Alpert Medical School of Brown University, Providence, RI; Cooper Medical School of Rowan University, Camden, NJ; Department of Intensive Care, Erasme University Hospital, Brussels, Belgium; National Institutes of Health, Bethesda, MD; University of Pittsburgh School of Medicine, Pittsburgh, PA.

No abstract available

Comment on

The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*.
Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. Opal SM, et al. Crit Care Med. 2014 Jul;42(7):1714-21. doi: 10.1097/CCM.0000000000000325. Crit Care Med. 2014. PMID: 24717456 Free PMC article.
Addressing the global burden of sepsis: importance of a systems-based approach.
Dobson GP. Dobson GP. Crit Care Med. 2014 Dec;42(12):e797-8. doi: 10.1097/CCM.0000000000000595. Crit Care Med. 2014. PMID: 25402302 No abstract available.